Methods and pharmaceutical compositions for treating age-related diseases
AssigneeNeurxstem
InventorRene ANAND
Life of this patent
Estimating the term…
Abstract
Methods for using gene expression changes and mutations in neural organoids to identify and assess effectiveness of treatment methodologies and effective pharmaceutical compositions for treating a disease, disorder, or disability as a consequence of biological aging are disclosed.
Claims40
A method for reducing or ameliorating disease severity in an individual for a disease, disorder, or disability as a consequence of biological aging comprising administering to the individual a therapeutically effective amount of a pharmaceutical composition comprising a drug capable of reducing or correcting dysfunctional expression of genes related to said disease or disability as a consequence of biological aging in vitro in a neural organoid platform and reducing or ameliorating disease severity in an individual thereby.
A pharmaceutical composition of a drug capable of reducing or ameliorating disease severity in an individual having a disease, disorder, or disability as a consequence of biological aging comprising a therapeutically effective amount of the pharmaceutical composition comprising a drug capable of reducing or correcting dysfunctional expression of genes in vitro in a neural organoid platform that reduces or ameliorates disease severity in an individual thereby.
The pharmaceutical composition of claim, wherein the endocannabinoid anandamide receptor is encoded by a CNR1 gene (Genbank Accession No. NM_016083.6).
A method for performing gene therapy in a cell to correct expression of one or a plurality of adenosine receptor network components identified as ADORA1, ADORA2A, ADORA2B and CNR1, and EZH2 genes and their modulators resulting in modification of gene expression in the one or a plurality of components.
A method for treating aging including age-related dementia and cancers in a human, using a patient-specific pharmacotherapy, the method comprising:
- a) procuring one or a plurality of cell samples from a patient, comprising one or a plurality of cell types including but not limited to fibroblasts, buccal cavity cells, or peripheral blood monocytes;
- b) detecting genes from the procured one or a plurality of cell samples that are differentially expressed, wherein these genes are also differentially expressed in humans with accelerated aging including age-related dementia and cancers;
- c) preparing a neural organoid from the procured one or a plurality of cell samples and detecting additional genes that are differentially expressed compared to neural organoid obtained from a healthy patient;
- d) performing assays on the neural organoid from the procured one or a plurality of cell samples to identify therapeutic agents that alter one or more of the differentially expressed genes detected in b) and c);
- and
- d) administering one or more of the therapeutic agents for aging including age-related dementia and cancers to treat the patient.
Dependencies are inferred from the claim text.